[Lethal diabetic ketoacidosis in a schizophrenic patient].
Povlsen
Uffe Juul
UJ
H:S Rigshospitalet, Psykiatrisk Klinik, København. juul.povlsen@rh.dk
Lublin
Henrik
H
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003511:Cyclohexanols / Q000009:adverse effects; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D003987:Dibenzothiazepines / Q000009:adverse effects; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D000069348:Quetiapine Fumarate; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D000069470:Venlafaxine Hydrochloride; D015430:Weight Gain / Q000187:drug effects
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D003511:Cyclohexanols; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride
Letal diabetisk ketoacidose hos en skizofren patient.